Valentin Brodszky1, Fanni Rencz1,2, Márta Péntek1, Petra Baji1, Péter L Lakatos3, László Gulácsi1. 1. a 1 Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary. 2. b 2 Semmelweis University Doctoral School of Clinical Medicine, Üllői út 26, H-1085 Budapest, Hungary. 3. c 3 First Department of Medicine, Semmelweis University, Koranyi S. 2/A, H-1083 Budapest, Hungary.
Abstract
OBJECTIVES: To estimate the budget impact of the introduction of biosimilar infliximab for the treatment of Crohn's disease (CD) in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. METHODS: A 3-year, prevalence-based budget impact analysis for biosimilar infliximab to treat CD was developed from third-party payers' perspective. The model included various scenarios depending on whether interchanging originator infliximab with biosimilar infliximab was allowed or not. RESULTS: Total cost savings achieved in biosimilar scenario 1 (interchanging not allowed) and BSc2 (interchanging allowed in 80% of the patients) were estimated to €8.0 million and €16.9 million in the six countries. Budget savings may cover the biosimilar infliximab therapy for 722-1530 additional CD patients. CONCLUSIONS: Introduction of biosimilar infliximab to treat CD may offset the inequity in access to biological therapy for CD between Central and Eastern European countries.
OBJECTIVES: To estimate the budget impact of the introduction of biosimilar infliximab for the treatment of Crohn's disease (CD) in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. METHODS: A 3-year, prevalence-based budget impact analysis for biosimilar infliximab to treat CD was developed from third-party payers' perspective. The model included various scenarios depending on whether interchanging originator infliximab with biosimilar infliximab was allowed or not. RESULTS: Total cost savings achieved in biosimilar scenario 1 (interchanging not allowed) and BSc2 (interchanging allowed in 80% of the patients) were estimated to €8.0 million and €16.9 million in the six countries. Budget savings may cover the biosimilar infliximab therapy for 722-1530 additional CD patients. CONCLUSIONS: Introduction of biosimilar infliximab to treat CD may offset the inequity in access to biological therapy for CD between Central and Eastern European countries.
Entities:
Keywords:
Central and Eastern Europe; Crohn’s disease; biosimilar drugs; budget impact analysis; inflammatory bowel diseases; infliximab
Authors: Petra Baji; László Gulácsi; Valentin Brodszky; Zsuzsanna Végh; Silvio Danese; Peter M Irving; Laurent Peyrin-Biroulet; Stefan Schreiber; Fanni Rencz; Péter L Lakatos; Márta Péntek Journal: United European Gastroenterol J Date: 2017-05-08 Impact factor: 4.623